KR20110088598A - 혈관 질환 및 대사 질환 치료용 실로스타졸의 니트레이트 유도체 - Google Patents

혈관 질환 및 대사 질환 치료용 실로스타졸의 니트레이트 유도체 Download PDF

Info

Publication number
KR20110088598A
KR20110088598A KR1020117015258A KR20117015258A KR20110088598A KR 20110088598 A KR20110088598 A KR 20110088598A KR 1020117015258 A KR1020117015258 A KR 1020117015258A KR 20117015258 A KR20117015258 A KR 20117015258A KR 20110088598 A KR20110088598 A KR 20110088598A
Authority
KR
South Korea
Prior art keywords
compound
formula
vascular
metabolic diseases
cilostazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117015258A
Other languages
English (en)
Korean (ko)
Inventor
디르크 사르토르
아르민 쉐르하크
Original Assignee
카르디올린크스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카르디올린크스 아게 filed Critical 카르디올린크스 아게
Publication of KR20110088598A publication Critical patent/KR20110088598A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117015258A 2008-12-02 2009-12-01 혈관 질환 및 대사 질환 치료용 실로스타졸의 니트레이트 유도체 Withdrawn KR20110088598A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170435.5 2008-12-02
EP08170435A EP2194048A1 (en) 2008-12-02 2008-12-02 Nitrate esters for the treatment of vascular and metabolic diseases

Publications (1)

Publication Number Publication Date
KR20110088598A true KR20110088598A (ko) 2011-08-03

Family

ID=40456966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117015258A Withdrawn KR20110088598A (ko) 2008-12-02 2009-12-01 혈관 질환 및 대사 질환 치료용 실로스타졸의 니트레이트 유도체

Country Status (14)

Country Link
US (1) US8426597B2 (enExample)
EP (2) EP2194048A1 (enExample)
JP (1) JP2012510502A (enExample)
KR (1) KR20110088598A (enExample)
CN (1) CN102245583A (enExample)
AU (1) AU2009324123A1 (enExample)
BR (1) BRPI0923300A2 (enExample)
CA (1) CA2745252A1 (enExample)
IL (1) IL213214A0 (enExample)
MX (1) MX2011005744A (enExample)
RU (1) RU2011126607A (enExample)
SG (1) SG171423A1 (enExample)
WO (1) WO2010063724A1 (enExample)
ZA (1) ZA201104011B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
AR081268A1 (es) 2010-06-02 2012-07-18 Cardiolynx Ag Derivados de nitrato de pioglitazona
ES2822004T3 (es) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticuerpos contra quetiapina y uso de los mismos
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
ES2807902T3 (es) 2012-08-21 2021-02-24 Janssen Pharmaceutica Nv Anticuerpos para olanzapina y uso de los mismos
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
EP3415516B1 (en) 2012-08-21 2021-12-15 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
EP2888234B1 (en) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
EP3663316A1 (en) 2012-08-21 2020-06-10 Janssen Pharmaceutica NV Antibodies to aripiprazole and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
WO2014031630A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone and use thereof
US9303041B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CN114044766B (zh) * 2021-10-09 2022-12-27 张北北九食品检验技术有限公司 放射性同位素碳-14标记的呋虫胺和中间体及其制备方法和应用
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US6148496A (en) 1999-04-09 2000-11-21 The Procter & Gamble Company Method for making a seamless apertured metal belt
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
JP2007500684A (ja) 2003-07-31 2007-01-18 ニコックス エス エイ 心臓血管疾患治療用のアンギオテンシン−ｉｉ受容体遮断薬としてのロサルタン、バルサルタン、カンデサルタン、テルミサルタン、エプロサルタンおよびオルメサルタンのニトロオキシ誘導体
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
EP1922069A2 (en) * 2005-08-08 2008-05-21 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Also Published As

Publication number Publication date
RU2011126607A (ru) 2013-01-10
SG171423A1 (en) 2011-07-28
WO2010063724A1 (en) 2010-06-10
US8426597B2 (en) 2013-04-23
BRPI0923300A2 (pt) 2019-07-16
US20110230520A1 (en) 2011-09-22
JP2012510502A (ja) 2012-05-10
EP2367803A1 (en) 2011-09-28
IL213214A0 (en) 2011-07-31
ZA201104011B (en) 2012-02-29
EP2194048A1 (en) 2010-06-09
CA2745252A1 (en) 2010-06-10
AU2009324123A1 (en) 2011-07-21
MX2011005744A (es) 2011-06-20
CN102245583A (zh) 2011-11-16

Similar Documents

Publication Publication Date Title
KR20110088598A (ko) 혈관 질환 및 대사 질환 치료용 실로스타졸의 니트레이트 유도체
JP2020203939A (ja) 治療用化合物および組成物
US11248012B2 (en) Phospholipidation of imidazoquinolines and oxoadenines
CN101379059A (zh) N-羟基丙烯酰胺化合物
WO2003006670A2 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
RU2197478C2 (ru) Производные бифениламидина
US10064853B2 (en) Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
RU2201928C1 (ru) 4-гетероциклилсульфонамидил-6-метокси-5-(2-метоксифенокси)-2-пиридилпиримидиновые производные и фармацевтическая композиция
JP2003506353A (ja) 抗凝血物質としてのベンゼンアミン誘導体
CZ20004587A3 (en) Tetrahydroquinoline derivatives
CZ276092A3 (en) Heterocyclically substituted quinolylmethoxy-phenyl acetamides
CN112010774B (zh) FXIa凝血因子抑制剂、其药物组合物和用途
EP2917204B1 (fr) Derives de 1h-indole-3-carboxamide et leurs utilisation comme antagonistes du p2y12
JP5829619B2 (ja) トリアゾロン化合物のプロドラッグ
CN114736161A (zh) 咪唑烷基香草酸醚衍生物及其用途
JP2006527731A (ja) Ｘａ因子阻害剤としてのピロリジン−２−オン
US8729115B2 (en) Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
US7329685B2 (en) 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases
EP2377855B1 (en) A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases
US20240018117A1 (en) Prodrug compounds of 3,4-methylenedioxymethamphetamine (mdma) and methods of synthesizing the same
RU2376295C2 (ru) Производные пиримидинона и фармацевтическая композиция на их основе, обладающая свойствами ингибитора нейтрофильной эластазы человека
US20070203206A1 (en) 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors
JPWO1999026918A1 (ja) ビフェニルアミジン誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110701

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid